{"classes":[{"categories":[{"measurements":[{"comment":"Median was not achieved as only 7 events of SEGA progression were observed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median was not achieved as only 8 events of SEGA progression were observed.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median upper value was not available as only single of SEGA progression were observed.","groupId":"OG002","lowerLimit":"55.72","upperLimit":"NA","value":"55.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"111"}],"units":"Participants"}],"description":"Time to SEGA worsening was defined as the time from the start of everolimus to date of the first SEGA worsening. SEGA worsening was defined as either; increase from nadir of ≥ 25% in SEGA volume or unequivocal worsening of non-target SEGA lesions, or appearance of new SEGA lesion ≥ 1.0 cm in longest diameter, or new or worsening hydrocephalus. The median value was not reached in either treatment arm of core period as SEGA worsening was observed in less participants (everolimus - 7 and placebo - 8).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain the whole blood trough concentrations in range of 5-15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.","id":"OG000","title":"Everolimus (Core Period)"},{"description":"Participants received oral dose of placebo matching to everolimus daily.","id":"OG001","title":"Placebo (Core Period)"},{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain blood trough concentrations in range of 5-15 ng/mL.","id":"OG002","title":"Everolimus (Extension Period)"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in the FAS population. Here, \"Number of participants analysed\" signifies the participants assessed for time to SEGA worsening during the study for each arm, respectively.","reportingStatus":"POSTED","timeFrame":"Baseline up to week 48 (end of core period), and end of extension period (up to 4 years)","title":"Time to SEGA Worsening","type":"SECONDARY","unitOfMeasure":"months"}